ZA200802811B - Therapy for the treatment of disease - Google Patents

Therapy for the treatment of disease

Info

Publication number: ZA200802811B
Authority: ZA; South Africa
Prior art keywords: therapy; disease; treatment; disclosed; pharmaceutically acceptable
Prior art date: 2005-09-02

Application number

ZA200802811A

Other languages

English (en)

Inventor

Paborji Mehdi

Original Assignee

Theravida Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-02

Filing date

2006-08-28

Publication date

2009-09-30

2006-08-28 Application filed by Theravida Inc filed Critical Theravida Inc

2009-09-30 Publication of ZA200802811B publication Critical patent/ZA200802811B/xx

Links

201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
239000012458 free base Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 1
XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 abstract 1
206010020853 Hypertonic bladder Diseases 0.000 abstract 1
208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 1
208000020629 overactive bladder Diseases 0.000 abstract 1
229960005434 oxybutynin Drugs 0.000 abstract 1
229960001416 pilocarpine Drugs 0.000 abstract 1
229960004045 tolterodine Drugs 0.000 abstract 1
OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract 1
BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Botany (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Percussion Or Vibration Massage (AREA)

ZA200802811A 2005-09-02 2006-08-28 Therapy for the treatment of disease ZA200802811B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71415005P	2005-09-02	2005-09-02

Publications (1)

Publication Number	Publication Date
ZA200802811B true ZA200802811B (en)	2009-09-30

Family

ID=37502599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200802811A ZA200802811B (en)	2005-09-02	2006-08-28	Therapy for the treatment of disease

Country Status (19)

Country	Link
US (6)	US7678821B2 (de)
EP (1)	EP1933833B8 (de)
JP (1)	JP5312027B2 (de)
KR (1)	KR101054248B1 (de)
CN (2)	CN101287462A (de)
AT (1)	ATE506059T1 (de)
AU (1)	AU2006284940B2 (de)
BR (1)	BRPI0615432A2 (de)
CA (1)	CA2619565C (de)
DE (1)	DE602006021444D1 (de)
DK (1)	DK1933833T3 (de)
ES (1)	ES2365161T3 (de)
IL (1)	IL189546A (de)
NZ (1)	NZ565840A (de)
PL (1)	PL1933833T3 (de)
PT (1)	PT1933833E (de)
RU (1)	RU2435610C2 (de)
WO (1)	WO2007027675A1 (de)
ZA (1)	ZA200802811B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1933833T3 (pl) *	2005-09-02	2011-09-30	Theravida Inc	Terapia do leczenia pęcherza nadreaktywnego
JP5637551B2 (ja) *	2005-12-28	2014-12-10	キッセイ薬品工業株式会社	唾液腺障害の治療用医薬
WO2009080061A1 (en) *	2007-12-20	2009-07-02	Pharmathen S.A.	Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US10265311B2 (en)	2009-07-22	2019-04-23	PureTech Health LLC	Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (de) *	2009-07-22	2019-07-10	Puretech Health LLC	Zusammensetzungen zur behandlung von durch muscarinrezeptoraktivierung gelinderten leiden
SG174658A1 (en)	2010-04-01	2011-10-28	Theravida Inc	Pharmaceutical formulations for the treatment of overactive bladder
KR20130065650A (ko) *	2010-04-01	2013-06-19	테라비다, 인코포레이티드	수면의 질 개선 방법
CN102325467B (zh) *	2010-05-12	2013-10-09	沈宝美	根据体质不同的用于改善便秘的天然食品组合物
KR20130045332A (ko) *	2010-06-22	2013-05-03	지아시앙 차오	항콜린제를 포함하는 질내 기구 및 그 제조방법
US9119878B2 (en)	2010-07-08	2015-09-01	Wellesley Pharmaceuticals, Llc	Extended-release formulation for reducing the frequency of urination and method of use thereof
KR101932714B1 (ko) *	2010-09-28	2018-12-26	삼성전자주식회사	소셜 그룹 생성 및 연결 방법, 그 방법을 수행할 수 있는 유저 디바이스, 서버 및 저장 매체
WO2012154776A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of trospium and salivary stimulants for the treatment of overactive bladder
WO2012154892A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
US20120289560A1 (en)	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
WO2012154779A1 (en) *	2011-05-10	2012-11-15	Theravida. Inc.	Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
WO2012154771A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder
WO2012154774A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
WO2012154778A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder
US20120289562A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
MY174090A (en) *	2012-03-19	2020-03-09	Wellesley Pharmaceuticals Llc	Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2013166180A1 (en)	2012-05-01	2013-11-07	Theravida, Inc.	Methods for the treatment of overactive bladder
US10596127B2 (en)	2013-03-14	2020-03-24	Wellesley Pharmaceuticals, Llc	Composition for reducing the frequency of urination, method of making and use thereof
IL299897B2 (en)	2013-08-19	2024-02-01	Taris Biomedical Llc	Devices and methods for administering multiple units of drug
EP3237057B1 (de)	2014-12-23	2022-08-24	University of Pittsburgh - Of the Commonwealth System of Higher Education	Vorrichtungen und systeme zur behandlung von urologischen und magen-darm-erkrankungen durch elektrische stimulierung des fusses
US10596139B2 (en)	2015-03-06	2020-03-24	Chase Pharmaceuticals Corporation	Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017127073A1 (en)	2016-01-20	2017-07-27	Theravida, Inc.	Methods and compositions for treating hyperhidrosis
EP4066830A1 (de)	2018-04-24	2022-10-05	Allergan, Inc.	Verwendung von pilocarpinhydrochlorid zur behandlung von augenkrankheiten
AU2019315957A1 (en)	2018-08-01	2021-02-18	Taris Biomedical Llc	Methods of treating overactive bladder using trospium
IL281809B (en)	2018-09-28	2022-09-01	Karuna Therapeutics Inc	Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors
EP3967311A1 (de)	2020-09-11	2022-03-16	Astellas Pharma Inc.	Verbindungen zur verwendung bei der behandlung von mundtrockenheit
US11564909B2 (en)	2020-11-30	2023-01-31	Romeg Therapeutics Llc	Methods and compositions for oral pilocarpine liquid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6096756A (en)	1992-09-21	2000-08-01	Albert Einstein College Of Medicine Of Yeshiva University	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
CN1204890C (zh)	1997-12-22	2005-06-08	欧罗赛铁克股份有限公司	防止阿片样物质滥用的方法
DK1685839T3 (da)	1997-12-22	2013-06-24	Euro Celtique Sa	Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US6482837B1 (en)	1998-04-24	2002-11-19	University Of Rochester	Antimuscarinic compounds and methods for treatment of bladder diseases
US20030018061A1 (en) *	2000-01-28	2003-01-23	Kohei Ogawa	Novel remedies with the use of beta 3 agonist
US6716449B2 (en)	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
WO2006132196A1 (ja) *	2005-06-08	2006-12-14	Asahi Kasei Pharma Corporation	β３作動薬を含有する新規な医薬
PL1933833T3 (pl) *	2005-09-02	2011-09-30	Theravida Inc	Terapia do leczenia pęcherza nadreaktywnego

2006
- 2006-08-28 PL PL06813885T patent/PL1933833T3/pl unknown
- 2006-08-28 WO PCT/US2006/033671 patent/WO2007027675A1/en not_active Ceased
- 2006-08-28 CN CNA2006800320978A patent/CN101287462A/zh active Pending
- 2006-08-28 JP JP2008529187A patent/JP5312027B2/ja not_active Expired - Fee Related
- 2006-08-28 AT AT06813885T patent/ATE506059T1/de active
- 2006-08-28 DK DK06813885.8T patent/DK1933833T3/da active
- 2006-08-28 ES ES06813885T patent/ES2365161T3/es active Active
- 2006-08-28 CN CN2013100336427A patent/CN103142586A/zh active Pending
- 2006-08-28 AU AU2006284940A patent/AU2006284940B2/en active Active
- 2006-08-28 RU RU2008112687/15A patent/RU2435610C2/ru not_active IP Right Cessation
- 2006-08-28 EP EP06813885A patent/EP1933833B8/de not_active Not-in-force
- 2006-08-28 KR KR1020087005797A patent/KR101054248B1/ko not_active Expired - Fee Related
- 2006-08-28 ZA ZA200802811A patent/ZA200802811B/xx unknown
- 2006-08-28 PT PT06813885T patent/PT1933833E/pt unknown
- 2006-08-28 DE DE602006021444T patent/DE602006021444D1/de active Active
- 2006-08-28 NZ NZ565840A patent/NZ565840A/en not_active IP Right Cessation
- 2006-08-28 US US11/467,760 patent/US7678821B2/en active Active
- 2006-08-28 BR BRPI0615432-8A patent/BRPI0615432A2/pt not_active IP Right Cessation
- 2006-08-28 CA CA2619565A patent/CA2619565C/en active Active
2008
- 2008-02-14 IL IL189546A patent/IL189546A/en not_active IP Right Cessation
2009
- 2009-07-15 US US12/503,432 patent/US20090275629A1/en not_active Abandoned
- 2009-09-08 US US12/555,806 patent/US7666894B2/en active Active
2010
- 2010-02-22 US US12/710,301 patent/US8470864B2/en active Active
- 2010-02-22 US US12/710,310 patent/US7781472B2/en not_active Expired - Fee Related
2013
- 2013-06-24 US US13/925,220 patent/US20130289087A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100152263A1 (en)	2010-06-17
EP1933833A1 (de)	2008-06-25
US20130289087A1 (en)	2013-10-31
BRPI0615432A2 (pt)	2011-05-17
AU2006284940B2 (en)	2012-03-22
US7781472B2 (en)	2010-08-24
US8470864B2 (en)	2013-06-25
JP5312027B2 (ja)	2013-10-09
PT1933833E (pt)	2011-07-08
DK1933833T3 (da)	2011-07-25
US20070053995A1 (en)	2007-03-08
US7666894B2 (en)	2010-02-23
DE602006021444D1 (de)	2011-06-01
PL1933833T3 (pl)	2011-09-30
KR20080059155A (ko)	2008-06-26
CN101287462A (zh)	2008-10-15
CA2619565A1 (en)	2007-03-08
US20100137392A1 (en)	2010-06-03
NZ565840A (en)	2011-07-29
IL189546A0 (en)	2008-08-07
US7678821B2 (en)	2010-03-16
ATE506059T1 (de)	2011-05-15
CN103142586A (zh)	2013-06-12
CA2619565C (en)	2015-06-23
IL189546A (en)	2014-08-31
JP2009507021A (ja)	2009-02-19
WO2007027675A1 (en)	2007-03-08
RU2008112687A (ru)	2009-10-10
ES2365161T3 (es)	2011-09-23
EP1933833B8 (de)	2011-09-14
EP1933833B1 (de)	2011-04-20
US20090318522A1 (en)	2009-12-24
KR101054248B1 (ko)	2011-08-08
RU2435610C2 (ru)	2011-12-10
AU2006284940A1 (en)	2007-03-08
US20090275629A1 (en)	2009-11-05

Publication	Publication Date	Title
IL189546A0 (en)	2008-08-07	Therapy for the treatment of disease
AU2018256546A1 (en)	2018-11-22	Combination therapy with peptide epoxyketones
MY148108A (en)	2013-02-28	Medicaments for the treatment or prevention of fibrotic diseases
TW200806318A (en)	2008-02-01	Uses of anti-insulin-like growth factor I receptor antibodies
WO2006034373A3 (en)	2006-11-02	Variants and chemically-modified variants of phenylalanine ammonia-lyase
CA2883751A1 (en)	2014-03-13	Methods of treating alzheimer's disease and pharmaceutical compositions thereof
SG150531A1 (en)	2009-03-30	Use of meloxicam for the treatment of respiratory diseases in pigs
EA201270144A1 (ru)	2012-07-30	Комбинированная терапия при лечении диабета
CA3094580C (en)	2021-05-18	Oral formulations of cytidine analogs and methods of use thereof
AR060019A1 (es)	2008-05-21	Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
WO2004045593A3 (en)	2004-08-12	Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EA201492010A1 (ru)	2015-06-30	Применение высокой дозы лахинимода для лечения рассеянного склероза
NZ592615A (en)	2013-06-28	Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
EP4442321A3 (de)	2025-01-01	Methoden zur behandlung von sjögren-syndrom mit einem hemmer von bruton-kinase
EA201171087A1 (ru)	2012-02-28	СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
SE0400184D0 (sv)	2004-01-30	New therapeutical use
DE60218193D1 (de)	2007-03-29	Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
WO2007062093A3 (en)	2008-10-23	Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
EP1262197A3 (de)	2002-12-18	Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
EA201270298A1 (ru)	2012-12-28	Способ лечения злокачественной опухоли
TW200637544A (en)	2006-11-01	Medicaments for the treatment or prevention of fibrotic diseases
NZ592613A (en)	2013-06-28	Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
TW200635595A (en)	2006-10-16	Medicaments for the treatment of prevention of fibrotic diseases
WO2022026622A3 (en)	2022-03-31	Treatment of viral diseases
RU2013149635A (ru)	2015-06-20	Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря